IP Library Granted Patent US 8,609,634
Granted Patent B2
US 8,609,634 · App. 11/803,873 · Granted Dec 17, 2013

Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,609,634
App. No.
11/803,873
Granted
Dec 17, 2013
Kind
B2
Abstract

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).

Claims (16)

1. A method for preparing a preserved hyaluronic acid composition, the method comprising:

dissolving/diluting in a first quantity of a first aqueous solvent a cationic preservative that is benzalkonium chloride, to form a first volume of the first solution having a cationic preservative concentration of from about 0.001% to about 0.02%;

dissolving hyaluronic acid (HA) or physiologically-acceptable salt thereof separately in a second quantity of a second aqueous solvent to form a second volume of the second solution having an HA concentration of at least 0.001%; and

combining the first solution of dissolved cationic preservative with the second solution of dissolved HA or physiologically-acceptable salt thereof to form a third solution of volume equal to the total volume of the first volume and the second volume;

wherein the first quantity of the first solvent to the second quantity of the second solvent is between about 1.8:1 and about 2.2:1 by volume;

and wherein the third solution has a transmittance between about 93% and about 98% at 440 nm before filtration.

2. The method of claim 1 , wherein the benzalkonium chloride has the formula: [C 6 H 5 CH 2 N(CH 3 )R]Cl, wherein R is an alkyl group having between eight and 18 carbon atoms.

3. The method of claim 1 , wherein the benzalkonium chloride is in solution form for dilution with the first quantity of the first aqueous solvent.

4. The method of claim 1 , wherein the physiologically-acceptable salt is sodium hyaluronate.

5. The method of claim 1 , wherein the HA has a molecular weight between about 500,000 daltons and about 4,000,000 daltons.

6. The method of claim 5 , wherein the molecular weight is between about 1,000,000 daltons and about 2,000,000 daltons.

7. The method of claim 1 , wherein the ratio is about 2:1 by volume.

8. The method of claim 1 , wherein the first and/or second aqueous solvent further includes at least one of the following: glycerin, polyethylene glycol, and propylene glycol.

9. The method of claim 1 , further comprising:

filtering the third solution.

10. The method of claim 9 , wherein the third solution has a transmittance between about 95% and about 100% at 440 nm after filtration.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Jul 1, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036042/0443 →